Scalia's death will affect ACA-related Supreme Court case

A recent question-and-answer article prepared by the Associated Press and published by the Chicago Tribune (and others) examined the impact Supreme Court Justice Antonin Scalia’s death could have on existing cases in 2016.

One specific case the Supreme Court is scheduled to rule on involves President Obama’s signature Affordable Care Act.

“The Supreme Court will be looking at the health care law for the fourth time since its 2010 enactment,” the article read. “This time, the focus is on the arrangement the Obama administration worked out to spare faith-based hospitals, colleges and charities from paying for contraceptives for women covered under their health plans, while still ensuring that those women can obtain birth control at no extra cost as the law requires. The faith-based groups argue that the accommodation still makes them complicit in providing contraception to which they have religious objections. A tie vote here would sow rather than alleviate confusion because the appellate courts that have looked at the issue have not all come out the same way.”

The article also looks at additional cases the Court is scheduled to rule on this year, the history of election year Court nominations, and more. Click below to read the full text: 

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.